Business
Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-118 for the Treatment of CLN1 Disease
Virtual event on Monday, August 30, 2021, at 10:00 a.m. ET will provide an overview of CLN1 disease, discuss natural history, the TSHA-118 program and
About this update from Taysha Gene Therapies, Inc.
[{"type":"text","content":"\nVirtual event on Monday, August 30, 2021, at 10:00 a.m. ET will provide an overview of CLN1 disease, discuss natural history, the TSHA-118 program and clinical development strategy\n\n DALLAS--(BUSINESS WIRE)--\nTaysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced it will host a virtual key opinion leader (KOL) webinar on TSHA-118 for the treatment of CLN1 disease on Monday, August 30, 2021, from 10:00 a.m. to 12:30 p.m. ET.\n\nThe event will feature a presentation from key opinion leader Angela Schulz, M.D., Ph.D., University Medical Center Hamburg-Eppendorf, who will provide an overview of CLN1 disease, a severe, neurodegenerative lysosomal storage disease with no approved treatment, and discuss the natural history of the disease.\n\nTopics of discussion will also include the patient and caregiver perspective on the burden of disease, preclinical pharmacology and toxicology data for TSHA-118, and the clinical development strategy for the TSHA-118 program. A question and answer session will follow each formal presentation.\n\nThe event will feature presentations from:\n\n\nSharon King, President of Taylor’s Tale, who will discuss the burden of disease and provide a patient and caregiver perspective\n\n\nSteven Gray, Ph.D., Associate Professor in the Department of Pediatrics at UT Southwestern and Chief Scientific Advisor at Taysha, who will review the preclinical and pharmacology data for TSHA-118 for the treatment of CLN1 disease\n\n\nSuyash Prasad, MBBS, M.Sc., MRCP, MRCPCH, FFPM, CMO and Head of R&D of Taysha, who will discuss the clinical development strategy for TSHA-118\n\n\nRegistration for this event is available through LifeSci Events. A live video webcast will be available in the “Events & Media” section of the Taysha corporate website. An archived version of the event will be available on the website for 60 days.\n\nAbout Taysha Gene Therapies \n\nTaysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined ...